

WORLDWIDE APPROVAL

TRIUMEQ Tablets

Albania	Guatemala	Nigeria
Argentina	Guyana	Oman
Armenia	Haiti	Pakistan
Aruba	Honduras	Panama
Australia	Hong Kong	Peru
Azerbaijan	Israel	Qatar
Bahrain	Jamaica	Republic of Korea
Bosnia and Herzegovina	Japan	Saudi Arabia
Botswana	Jordan	Serbia
Brazil	Kazakhstan	Singapore
Canada	Kenya	South Africa
Chile	Kuwait	Switzerland
China	Kyrgyzstan	Taiwan
Colombia	Lebanon	Thailand
Costa Rica	Macau	Trinidad and Tobago
Curacao	Macedonia	Turkey
Dominican Republic	Mexico	Uganda
Ecuador	Moldova	Ukraine
El Salvador	Mongolia	United Arab Emirates
European Union	Morocco	United States of America
Georgia	Namibia	Uruguay
Ghana	New Zealand	Uzbekistan

- ✓ "Approval" means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.
- ✓ Granted Marketing Authorisations may include limitations on the use of the product.

This document was prepared on 07 Sep 2021 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.